Tandem backs up efficacy of Mobi
By HME News Staff
Updated 8:52 AM CDT, Tue June 25, 2024
SAN DIEGO – Eighty-six percent of participants were satisfied or very satisfied with Tandem Diabetes Care’s Mobi regardless of prior therapy and agreed the automated insulin delivery system improves their quality of life, according to survey results the company presented at the 84th Scientific Sessions of the American Diabetes Association. “These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with diabetes by demonstrating that Tandem Mobi not only meets but exceeds user expectations,” said Jordan Pinsker, MD, chief medical officer at Tandem Diabetes Care. “We are proud to share these results at ADA and will continue to innovate to provide the diabetes community with choice and improved quality of life.” In the six-week limited launch survey, early users who were previously using multiple daily injections (MDI) or other insulin pumps (tubed and tubeless) or were previous Tandem pump users also exhibited high satisfaction with the Mobi combined with the Control-IQ algorithm. The company also shared at ADA insights from an independent study involving Tandem Mobi users that showed their time in range improved with no increase in time spent below range. The company made Mobi commercially available in the United States in February.
Comments